Clinical Trials Logo

Clinical Trial Summary

A Multicenter, Open-label, Phase I Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of HMPL-760 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma


Clinical Trial Description

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of HMPL-760 administered orally in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL). Patients with relapsed/refractory B-NHL, including chronic lymphocytic leukemia/small cell lymphoma (CLL/SLL), diffuse large B-cell lymphoma (DLBCL), follicular cell lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and lymphoplasmacytic/macroglobulinemia (LPL/WM). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05190068
Study type Interventional
Source Hutchison Medipharma Limited
Contact Yujie Wang, Ph.D
Phone 021-20671795
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date January 2022
Completion date April 2026

See also
  Status Clinical Trial Phase
Completed NCT00588094 - Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL Phase 2
Not yet recruiting NCT05091541 - A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Phase 1/Phase 2
Recruiting NCT03639181 - Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226) Phase 2
Recruiting NCT04746131 - Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL) Phase 1
Terminated NCT01352312 - Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma Phase 1
Not yet recruiting NCT04697290 - CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients. Early Phase 1
Completed NCT02564744 - Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL Phase 2
Active, not recruiting NCT00927797 - Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL) Phase 2
Not yet recruiting NCT03105596 - Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL) Phase 2